R&D at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's R&D?
- BridgeBio Pharma (BBIO) reported R&D of $126.64M in Q1 2026.
- How has BridgeBio Pharma's R&D changed year-over-year?
- BridgeBio Pharma's R&D increased by 13.6% year-over-year, from $111.43M to $126.64M.
- What is the long-term trend for BridgeBio Pharma's R&D?
- Over 4 years (2021 to 2025), BridgeBio Pharma's R&D has grown at a 0.1% compound annual growth rate (CAGR), from $451.02M to $451.95M.
- What does R&D mean?
- The total spending on scientific research and clinical trials to develop new products.
- How do you interpret R&D?
- Higher spending reflects an aggressive pipeline advancement strategy, while lower spending may indicate a focus on cost-cutting or a pause in clinical development.
- How does R&D compare across companies?
- High R&D intensity is standard for biotech firms, often exceeding total revenue in early-stage companies.